This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Gene Therapy Open Access 22 March 2021
-
Conventional CARs versus modular CARs
Cancer Immunology, Immunotherapy Open Access 21 September 2019
-
An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
Scientific Reports Open Access 22 July 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Robak T, Wierzbowska A . Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009; 31: 2349–2370.
Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID . Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986; 67: 1048–1053.
Hauswirth AW, Florian S, Printz D, Sotlar K, Krauth MT, Fritsch G et al. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest 2007; 37: 73–82.
Horton SJ, Huntly BJ . Recent advances in acute myeloid leukemia stem cell biology. Haematologica 2012; 97: 966–974.
Walter RB, Appelbaum FR, Estey EH, Bernstein ID . Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198–6208.
Aigner M, Feulner J, Schaffer S, Kischel R, Kufer P, Schneider K et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE(®) antibody construct. Leukemia 2012; e-pub ahead of print 14 December 2012 doi:10.1038/leu.2012.341.
Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086–4092.
Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 2011; 49: 474–482.
Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia 2011; 25: 1053–1056.
Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 2012; 189: 3249–3459.
Koristka S, Cartellieri M, Theil A, Feldmann A, Arndt A, Stamova S et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol 2012; 188: 1551–1558.
Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33+ acute myeloid leukemia. Adv Hematol 2012; 2012: 683065.
Robertson MJ, Soiffer RJ, Freedmann AA, Rabinowe SL, Anderson KC, Ervin TJ . Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992; 79: 2229–2236.
Jing D, Fonseca AV, Alakel N, Fierro FA, Muller K, Bornhauser M et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells--modeling the niche compartments in vitro. Haematologica 2010; 4: 542–550.
Acknowledgements
We thank Livia Schulze, Kristin Heidel, Barbara Uteß and Christine Gräfe for excellent technical assistance, Professor Dr Dirk Lindemann for providing us with the lentiviral vector system, and Professor Dr Christian Thiede for providing the CD33+ cell lines MOLM-13, MV4-11 and OCI-AML3. This study was supported by grants of the Medical faculty of the TU Dresden to MC and the Deutsche José Carreras Leukämie-Stiftung e.V. to MB.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
MB, SS and GE have filed patent applications related to the Ab directed to CD33. The remaining authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Arndt, C., von Bonin, M., Cartellieri, M. et al. Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 27, 964–967 (2013). https://doi.org/10.1038/leu.2013.18
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.18
This article is cited by
-
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Gene Therapy (2021)
-
An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
Scientific Reports (2019)
-
Conventional CARs versus modular CARs
Cancer Immunology, Immunotherapy (2019)
-
Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia
Current Hematologic Malignancy Reports (2018)
-
Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding
Scientific Reports (2017)